Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Sintilimab (Synonyms: Sintilimab (anti-PD-1), IBI308)

Catalog No. T35394 Copy Product Info
🥰Excellent
Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody with significant anti-tumor activity that restores endogenous anti-tumor T-cell responses by binding to PD-1 and thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2).Sintilimab is used in combination with other compounds for the treatment of classical Hodgkin's lymphoma, non-cellular lung cancer and esophageal cancer. Sintilimab is used in combination with other compounds to treat classical Hodgkin's lymphoma, non-small cell lung cancer and esophageal cancer.

Sintilimab

Copy Product Info
🥰Excellent
Catalog No. T35394
Synonyms Sintilimab (anti-PD-1), IBI308

Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody with significant anti-tumor activity that restores endogenous anti-tumor T-cell responses by binding to PD-1 and thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2).Sintilimab is used in combination with other compounds for the treatment of classical Hodgkin's lymphoma, non-cellular lung cancer and esophageal cancer. Sintilimab is used in combination with other compounds to treat classical Hodgkin's lymphoma, non-small cell lung cancer and esophageal cancer.

Sintilimab
Cas No. 2072873-06-2
TargetMol | Customer service
Customer service consultation
Pack SizePriceUSA StockGlobal StockQuantity
1 mg$163In StockIn Stock
5 mg$428In StockIn Stock
10 mg$733-In Stock
25 mg$1,090-In Stock
50 mg$1,480-In Stock
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:>95.0% (SDS-PAGE); 95.0% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information

Product Introduction

Bioactivity
Description
Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody with significant anti-tumor activity that restores endogenous anti-tumor T-cell responses by binding to PD-1 and thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2).Sintilimab is used in combination with other compounds for the treatment of classical Hodgkin's lymphoma, non-cellular lung cancer and esophageal cancer. Sintilimab is used in combination with other compounds to treat classical Hodgkin's lymphoma, non-small cell lung cancer and esophageal cancer.
SynonymsSintilimab (anti-PD-1), IBI308
Reactivity
Human
Verified Activity
Immobilized PD-1 Protein (His) at 2 μg/mL (30 μL/well) can bind Sintilimab. The EC50 of 6.827 ng/mL.
verifiedActivityverifiedActivity
Application
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Gene ID
Uniprot ID
TargetPDCD1/PD-1/CD279
Chemical Properties
Molecular Weight143.78 kDa
Cas No.2072873-06-2
Antibody Information
IsotypeHuman IgG4SP kappa
Recommended Isotype Control
Storage & Solubility Information
Storage-20°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Citations

Calculator

  • Dilution Calculator
  • Reconstitution Calculator

Keywords

Related Tags: buy Sintilimab | purchase Sintilimab | Sintilimab cost | order Sintilimab | Sintilimab molecular weight